Synlogic Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Synlogic Therapeutics's estimated annual revenue is currently $13.8M per year.
- Synlogic Therapeutics received $30.0M in venture funding in April 2018.
- Synlogic Therapeutics's estimated revenue per employee is $155,000
- Synlogic Therapeutics's total funding is $176.9M.
- Synlogic Therapeutics has 89 Employees.
- Synlogic Therapeutics grew their employee count by -5% last year.
- Synlogic Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Synlogic Therapeutics?
At Synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. Using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these synthetic biotics orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease (IBD), cancer and metabolic conditions such as diabetes and obesity. Learn more on our website at www.synlogictx.com.keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Chang Hong||Corporate Counsel & Head Of Intellectual Property|
|Aoife Brennan||Ceo||Email Available|
|Caroline Kurtz||Svp,head Of Metabolism||Email Available|
|Ning Li||Principal Scientist||Email Available|
|Michael Slater||Head Of Regulatory Affairs|
|Brad Smith||Associate Director, Fp&a Lead|
|Kip West||Director Of Immunomodulation||Email Available|
|Katherine Heang||In Vivo Operations Manager|
|Philippa Reeder||Upstream Team Leader - Principal Scientist|
|Tracy Kane||Director, Interim Program Leader|
Synlogic Therapeutics News
Synlogic, Inc. (SYBX), a clinical stage company applying synthetic ... its ability to advance these novel therapeutics into clinical trials,” stated Dr.
Synlogic has initiated a bridging study of a new solid formulation of ... to deliver novel medicines designed to perform a therapeutic function.”.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying ... its ability to advance these novel therapeutics into clinical trials,” stated Dr.
Synlogic Therapeutics Funding
|2014-10-08||$5.0M||A||Bill & Melinda Gates||Article|
|2016-02-18||$40.0M||B||OrbiMed HealthCare Fund Management||Article|
Synlogic Therapeutics Executive Hires
|2016-12-16||Samantha Truex||COO /Head of Corporate Development.||Article|
|2017-10-11||Andrew Gengos||COO/Head of Corporate Development||Article|
|2018-05-11||Aoife Brennan||Interim President/CEO||Article|
|2018-10-03||Aoife Brennan||President & CEO||Article|
|2018-12-13||Antoine Awad||Head of Technical Operations||Article|
Synlogic Therapeutics Acquisitions
|2017-05-17||Mirna Therapeutics Inc.||Article|
|2017-08-29||Mirna Therapeutics Inc.||Article|